Skip to main content

Advertisement

Table 4 Antimicrobial activity of antimicrobial agents against Enterococcus and Staphylococcus spp. collected globally between 2004 - 2013

From: Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

  MIC 90 (mg/L) MIC range (mg/L) % susceptible % resistant
Enterococcus faecalis (n = 14,615)     
AMC 1 ≤0.03 – ≥ 16 - -
AMP 2 ≤0.06 – ≥ 32 99.4 0.6
CRO ≥128 ≤0.03 – ≥ 128 - -
IPM (n = 3,208) 4 ≤0.12 – ≥ 32 - -
LVX ≥64 ≤0.06 – ≥ 64 64.9 33.9
LIN 2 ≤0.5 – ≥ 16 99.8 <0.1
MEM (n = 11,407) 8 ≤0.12 – ≥ 32 - -
MIN ≥16 ≤0.25 – ≥ 16 34.8 28.2
PEN 4 ≤0.06 – ≥ 16 99.2 0.8
TZP 8 ≤0.25 – ≥ 32 - -
TGC 0.25 ≤0.008 – 2 99.7 -
VAN 2 ≤0.12 – ≥ 64 97.5 2.2
Enterococcus faecalis, VR (n = 325)     
AMC 2 0.06 – ≥ 16 - -
AMP 4 0.12 – ≥ 32 94.5 5.5
CRO ≥128 ≤0.03 – ≥ 128 - -
IPM (n = 98) 8 ≤0.12 – ≥ 32 - -
LVX ≥64 0.5 – ≥ 64 4.9 93.5
LIN 2 ≤0.5 – ≥ 16 98.5 1.2
MEM (n = 227) ≥32 ≤0.12 – ≥ 32 - -
MIN ≥16 ≤0.25 – ≥ 16 44.3 17.8
PEN 8 0.25 – ≥ 16 94.5 5.5
TZP 16 0.5 – ≥ 32 - -
TGC 0.25 ≤0.008 – 1 97.8 -
Enterococcus faecium (n = 6,167)     
AMC ≥16 ≤0.03 – ≥ 16 - -
AMP ≥32 ≤0.06 – ≥ 32 15.6 84.4
CRO ≥128 ≤0.03 – ≥ 128 - -
IPM (n = 1,162) ≥32 ≤0.12 – ≥ 32 - -
LVX ≥64 ≤0.06 – ≥ 64 13.1 83.6
LIN 2 ≤0.5 – ≥ 16 99.2 0.3
MEM (n = 5,005) ≥32 ≤0.12 – ≥ 32 - -
MIN ≥16 ≤0.25 – ≥ 16 68.5 14.3
PEN ≥16 ≤0.06 – ≥ 16 15.6 84.4
TZP ≥32 ≤0.25 – ≥ 32 - -
TGC 0.25 ≤0.008 – 4 99.7 -
VAN ≥64 ≤0.12 – ≥ 64 64.0 34.6
Enterococcus faecium, VR (n = 2,136)     
AMC ≥16 ≤0.03 – ≥ 16 - -
AMP ≥32 ≤0.06 – ≥ 32 1.5 98.5
CRO ≥128 ≤0.03 – ≥ 128 - -
IPM (n = 556) ≥32 0.5 – ≥ 32 - -
LVX ≥64 0.5 – ≥ 64 0.8 98.8
LIN 2 ≤0.5 – ≥ 16 98.4 0.7
MEM (n = 1,580) ≥32 ≤0.12 – ≥ 32 - -
MIN ≥16 ≤0.25 – ≥ 16 65.0 13.3
PEN ≥16 ≤0.06 – ≥ 16 1.7 98.3
TZP ≥32 ≤0.25 – ≥ 32 - -
TGC 0.12 ≤0.008 – 4 99.2 -
Staphylococcus aureus (n = 36,448)     
AMC ≥16 ≤0.03 – ≥ 16 - -
AMP ≥32 ≤0.06 – ≥ 32 - -
CRO ≥128 ≤0.03 – ≥ 128 - -
IPM (n = 7,302) 16 ≤0.12 – ≥ 32 - -
LVX 32 ≤0.06 – ≥ 64 64.1 34.3
LIN 4 ≤0.5 – ≥ 16 >99.9 <0.1
MEM (n = 29,146) 16 ≤0.12 – ≥ 32 - -
MIN 0.5 ≤0.25 – ≥ 16 97.3 0.9
PEN ≥16 ≤0.06 – ≥ 16 10.9 89.1
TZP ≥32 ≤0.25 – ≥ 32 - -
TGC 0.25 ≤0.008 – 1 99.9 -
VAN 1 ≤0.12 – 4 100 0
Staphylococcus aureus, MRSA (n = 14,647)    
AMC ≥16 ≤0.03 – ≥ 16 - -
CRO ≥128 ≤0.03 – ≥ 128 - -
IPM (n = 3,235) ≥32 ≤0.12 – ≥ 32 - -
LVX ≥64 ≤0.06 – ≥ 64 22.1 75.9
LIN 2 ≤0.5 – ≥ 16 99.9 <0.1
MEM (n = 11,412) ≥32 ≤0.12 – ≥ 32 - -
MIN 2 ≤0.25 – ≥ 16 94.7 1.7
TZP ≥32 ≤0.25 – ≥ 32 - -
TGC 0.25 ≤0.008 – 1 99.9 -
VAN 1 ≤0.12 – 4 99.9 0
  1. AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; AZM, azithromycin; FEP, cefepime; CAZ, ceftazidime; CLR, clarithromycin; CLI, clindamycin; CRO, ceftriaxone; ERY, erythromycin; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIN, minocycline; MRSA, methicillin-resistant S. aureus; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin; VR, vancomycin-resistant.